{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:14:14Z","timestamp":1792084454345,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Liposomal amphotericin B (L-AMB) is a broad-spectrum antifungal drug that is used to treat fungal infections. However, clinical evidence of its use in patients with renal failure is limited. Here, we aimed to identify factors associated with acute kidney injury (AKI) in patients administered L-AMB. We retrospectively utilized a combination of Diagnosis Procedure Combination data and laboratory data obtained from hospitals throughout Japan between April 2008 and January 2018. In total, 507 patients administered L-AMB were identified. After L-AMB treatment initiation, AKI, which was defined as a\u2009\u2265\u20091.5-fold increase within 7\u00a0days or\u2009\u2265\u20090.3\u00a0mg\/dL increase within 2\u00a0days in serum creatinine according to the KDIGO criteria, was recognized in 37% of the total patients (189\/507). The stages of AKI were stage 1 in 20%, stage 2 in 11%, and stage 3 in 7%. Five factors were associated with AKI of all stages: prior treatment with angiotensin-converting enzyme inhibitors\/angiotensin-receptor blockers or carbapenem; concomitant administration of catecholamines or immunosuppressants; and\u2009\u2265\u20093.52\u00a0mg\/kg\/day of L-AMB dosing. Serum potassium\u2009&lt;\u20093.5\u00a0mEq\/L before L-AMB therapy was associated with severe AKI of stage 2 and 3. Altogether, these factors should be carefully considered to reduce the occurrence of AKI in patients administered L-AMB.<\/jats:p>","DOI":"10.1038\/s41598-020-72135-y","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T10:03:01Z","timestamp":1600077781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan"],"prefix":"10.1038","volume":"10","author":[{"given":"Takahiro","family":"Takazono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Obata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaro","family":"Wakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"72135_CR1","doi-asserted-by":"publisher","first-page":"S289","DOI":"10.1080\/13693780400025237","volume":"43","author":"M Kleinberg","year":"2005","unstructured":"Kleinberg, M. Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Med. Mycol. 43, S289\u2013S294 (2005).","journal-title":"Med. Mycol."},{"key":"72135_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/01.qco.0000136935.13662.af","volume":"17","author":"JM Brown","year":"2004","unstructured":"Brown, J. M. Fungal infections in bone marrow transplant patients. Curr. Opin. Infect. Dis. 17, 347\u2013352 (2004).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"72135_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1086\/339202","volume":"34","author":"KA Marr","year":"2002","unstructured":"Marr, K. A., Carter, R. A., Crippa, F., Wald, A. & Corey, L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis 34, 909\u2013917 (2002).","journal-title":"Clin. Infect. Dis"},{"key":"72135_CR4","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1080\/13693780400020113","volume":"43","author":"J Morgan","year":"2005","unstructured":"Morgan, J. et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol. 43, S49\u2013S58 (2005).","journal-title":"Med. Mycol."},{"key":"72135_CR5","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1182\/asheducation-2003.1.438","volume":"1","author":"SN O\u2019Brien","year":"2003","unstructured":"O\u2019Brien, S. N., Blijlevens, N. M., Mahfouz, T. H. & Anaissie, E. J. Infections in patients with hematological cancer: recent developments. Hematol. Am. 1, 438\u2013472 (2003).","journal-title":"Hematol. Am."},{"key":"72135_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","volume":"76","author":"NR Stone","year":"2016","unstructured":"Stone, N. R., Bicanic, T., Salim, R. & Hope, W. Liposomal amphotericin B (AmBisome): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs 76, 485\u2013500 (2016).","journal-title":"Drugs"},{"key":"72135_CR7","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0149-2918(03)80125-X","volume":"25","author":"JP Barrett","year":"2003","unstructured":"Barrett, J. P. et al. Amphotericin B Systematic Review Study Group. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin. Ther. 25, 1295\u20131320 (2003).","journal-title":"Clin. Ther."},{"key":"72135_CR8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1517\/14740338.2013.827168","volume":"12","author":"AS Loo","year":"2013","unstructured":"Loo, A. S., Muhsin, S. A. & Walsh, T. J. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin. Drug Saf. 12, 881\u2013895 (2013).","journal-title":"Expert Opin. Drug Saf."},{"key":"72135_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.diagmicrobio.2017.10.018","volume":"90","author":"H Yamazaki","year":"2018","unstructured":"Yamazaki, H., Kondo, T., Aoki, K., Yamashita, K. & Takaori-Kondo, A. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: a retrospective analysis. Diagn. Microbiol. Infect. Dis. 90, 123\u2013131 (2018).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"72135_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.5649\/jjphcs.40.94","volume":"40","author":"Y Saito","year":"2014","unstructured":"Saito, Y. et al. Factor analysis in decreased expression of renal function by liposomal-amphotericin B. J. Pharm. Health Care Sci. 40, 94\u201399 (2014).","journal-title":"J. Pharm. Health Care Sci."},{"key":"72135_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"M Naesens","year":"2009","unstructured":"Naesens, M., Kuypers, D. R. J. & Sarwal, M. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 4, 481\u2013508 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"72135_CR12","first-page":"231","volume":"9","author":"EN Wardle","year":"1998","unstructured":"Wardle, E. N. Pathogenesis of acute renal failure: shock-kidneys. Saudi J. Kidney Dis. Transplant. 9, 231\u2013236 (1998).","journal-title":"Saudi J. Kidney Dis. Transplant."},{"key":"72135_CR13","doi-asserted-by":"publisher","first-page":"j791","DOI":"10.1136\/bmj.j791","volume":"356","author":"M Schmidt","year":"2017","unstructured":"Schmidt, M. et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ 356, j791 (2017).","journal-title":"BMJ"},{"key":"72135_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1155\/1998\/831425","volume":"9","author":"GG Zhanel","year":"1998","unstructured":"Zhanel, G. G., Simor, A. E., Vercaigne, L., Mandell, L. & Canadian Carbapenem Discussion Group. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can. J. Infect. Dis. 9, 215\u2013228 (1998).","journal-title":"Can. J. Infect. Dis."},{"key":"72135_CR15","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/ki.1992.229","volume":"41","author":"RA Zager","year":"1992","unstructured":"Zager, R. A., Bredl, C. R. & Schimpf, B. A. Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents. Kidney Int. 41, 1588\u20131594 (1992).","journal-title":"Kidney Int."},{"key":"72135_CR16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1681\/ASN.V4169","volume":"4","author":"SN Heyman","year":"1993","unstructured":"Heyman, S. N. et al. Chronic amphotericin nephropathy: morphometric, electron microscopic, and functional studies. J. Am. Soc. Nephrol. 4, 69\u201380 (1993).","journal-title":"J. Am. Soc. Nephrol."},{"key":"72135_CR17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1681\/ASN.V62154","volume":"6","author":"BP Sawaya","year":"1995","unstructured":"Sawaya, B. P., Briggs, J. P. & Schnermann, J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J. Am. Soc. Nephrol. 6, 154\u2013164 (1995).","journal-title":"J. Am. Soc. Nephrol."},{"key":"72135_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/0002-9343(83)90353-4","volume":"75","author":"HT Heidemann","year":"1983","unstructured":"Heidemann, H. T., Gerkens, J. F., Spickard, W. A., Jackson, E. K. & Branch, R. A. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am. J. Med. 75, 476\u2013481 (1983).","journal-title":"Am. J. Med."},{"key":"72135_CR19","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.ekir.2018.07.014","volume":"3","author":"HB Yalamanchili","year":"2018","unstructured":"Yalamanchili, H. B., Calp-Inal, S., Zhou, X. J. & Choudhury, D. Hypokalemic nephropathy. Kidney Int. Rep. 3, 1482\u20131488 (2018).","journal-title":"Kidney Int. Rep."},{"key":"72135_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1681\/ASN.2007030261","volume":"19","author":"S Reungjui","year":"2008","unstructured":"Reungjui, S. et al. Hypokalemic nephropathy is associated with impaired angiogenesis. J. Am. Soc. Nephrol. 19, 125\u2013134 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"72135_CR21","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1093\/ndt\/14.9.2216","volume":"14","author":"SA Menahem","year":"1999","unstructured":"Menahem, S. A., Perry, G. J., Dowling, J. & Thomson, N. M. Hypokalemia induced acute renal failure. Nephrol. Dial. Transplant. 14, 2216\u20132218 (1999).","journal-title":"Nephrol. Dial. Transplant."},{"key":"72135_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJM199002083220601","volume":"322","author":"VE Torres","year":"1990","unstructured":"Torres, V. E., Young, W. F., Offord, K. P. & Hattery, R. R. Association of hypokalemia, aldosteronism, and renal cysts. N. Engl. J. Med. 322, 345\u2013351 (1990).","journal-title":"N. Engl. J. Med."},{"key":"72135_CR23","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1515\/cclm-2016-0973","volume":"55","author":"K Kashani","year":"2017","unstructured":"Kashani, K., Cheungpasitporn, W. & Ronco, C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. Clin. Chem. Lab. Med. 55, 1074\u20131089 (2017).","journal-title":"Clin. Chem. Lab. Med."},{"key":"72135_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13613-017-0244-y","volume":"7","author":"T Tagami","year":"2017","unstructured":"Tagami, T. et al. Antithrombin use and 28-day in-hospital mortality among severe-burn patients: an observational nationwide study. Ann. Intensive Care. 7, 18 (2017).","journal-title":"Ann. Intensive Care."},{"key":"72135_CR25","unstructured":"KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2, 1 (2012)."},{"key":"72135_CR26","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53, 982\u2013992 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"72135_CR27","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/nep.12525","volume":"20","author":"C Thongprayoon","year":"2015","unstructured":"Thongprayoon, C. et al. Optimum methodology for estimating baseline serum creatinine for the acute kidney injury classification. Nephrology 20, 881\u2013886 (2015).","journal-title":"Nephrology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72135-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T18:36:56Z","timestamp":1670351816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72135-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["72135"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-72135-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"19 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.I. has received honorarium and research grant from Sumitomo Dainippon Pharma Co., Ltd. All the other authors do not have any competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15033"}}